Get the Stockscreener App
0.7542
3.86%
-0.0303
After Hours:
.75
-0.0042
-0.56%
Atossa Therapeutics Inc Stock (ATOS) Latest News
Atossa Therapeutics faces Nasdaq delisting over bid price By Investing.com - Investing.com South Africa
Atossa Therapeutics faces Nasdaq delisting over bid price - Investing.com
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Short Interest Up 5.8% in January - MarketBeat
Atossa Therapeutics reports progress in breast cancer treatments - MSN
Atossa Therapeutics Inc (ATOS) looking to reclaim success with recent performance - SETE News
Atossa Therapeutics (NASDAQ:ATOS) Stock Crosses Below 200 Day Moving AverageHere's Why - MarketBeat
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Bought by SG Americas Securities LLC - Defense World
Market Watch Highlights: Atossa Therapeutics Inc (ATOS) Ends on an Downturn Note at 0.77 - The Dwinnex
Investing in Atossa Therapeutics Inc (ATOS) Is Getting More Attractive - Knox Daily
Atossa Therapeutics faces patent setback, continues development - MSN
FY2029 Earnings Forecast for ATOS Issued By HC Wainwright - MarketBeat
What is HC Wainwright's Estimate for ATOS FY2029 Earnings? - MarketBeat
Atossa Therapeutics Congratulates Board Director Dr. Tessa - GlobeNewswire
Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care - The Manila Times
Major CDC Grant Fuels Revolutionary Breast Cancer Care Program in NYC - StockTitan
Do investors need to be concerned about Atossa Therapeutics Inc (ATOS)? - US Post News
Financial Metrics Unveiled: Atossa Therapeutics Inc (ATOS)’s Key Ratios in the Spotlight - The Dwinnex
Equities Analysts Set Expectations for ATOS FY2029 Earnings - Defense World
Atossa Therapeutics (NASDAQ:ATOS) Receives "Buy" Rating from HC Wainwright - MarketBeat
JPMorgan Chase & Co. Acquires 95,643 Shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
HC Wainwright Reiterates Buy Rating for Atossa Therapeutics (NASDAQ:ATOS) - Defense World
Atossa Genetics stock hits 52-week low at $0.75 - MSN
Atossa Genetics stock hits 52-week low at $0.75 By Investing.com - Investing.com Australia
Atossa Therapeutics Will Not Appeal PTAB Decision on Review of Patent Covering Endoxifen - Marketscreener.com
Troy Minerals Inc. (TROY-CN) QuotePress Release - The Globe and Mail
Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent - GlobeNewswire
Atossa's Patent Strategy Shift: New Endoxifen Patent Reinforces 118+ Protected Claims - StockTitan
Option Volatility And Earnings Report For January 2731 - The Globe and Mail
Apple Inc (AAPL-Q) QuotePress Release - The Globe and Mail
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025 - The Manila Times
Atossa Therapeutics reports progress in breast cancer treatments By Investing.com - Investing.com South Africa
Atossa's Endoxifen Shows Breakthrough 23.5% Breast Density Reduction in Phase 2 Cancer Trial - StockTitan
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Stake Raised by Barclays PLC - Defense World
Jane Street Group LLC Trims Stock Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Atossa Therapeutics (NASDAQ: ATOS) vs. NLS Pharmaceutics (NASDAQ: NLSP): A Comparative Analysis - HPBL
Head-To-Head Analysis: Atossa Therapeutics (NASDAQ:ATOS) & NLS Pharmaceutics (NASDAQ:NLSP) - Defense World
The Hidden Connection: Dr. Steven Quay on Alcohol and Cancer Risk - Cville Right Now
Atossa Therapeutics Applauds U.S. Surgeon General’s - GlobeNewswire
Surgeon General Links Alcohol to 44,000 Annual Breast Cancer Cases, Atossa Backs Warning - StockTitan
Geode Capital Management LLC Has $4.28 Million Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Barclays PLC Has $255,000 Stock Holdings in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
State Street Corp Has $2.63 Million Stock Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):